Stem cell memory T (T SCM ) and central memory T (T CM ) cells can rapidly differentiate into effector memory (T EM ) and terminal effector (T EF ) T cells, and have the most potential for immunotherapy. In this study, we found that the frequency of T SCM and T CM cells in the CD8+ population dramatically decreased together with increases in T EM and T EF cells, particularly in younger patients with acute myeloid leukemia (AML) (< 60 years). These alterations persisted in patients who achieved complete remission after chemotherapy. The decrease in T SCM and T CM together with the increase in differentiated T EM and T EF subsets in CD8+ T cells may explain the reduced T cell response and subdued anti-leukemia capacity in AML patients.
To the editor
Clinical applications of immunotherapy for AML lag behind those for solid tumors and lymphocytic leukemia [1] [2] [3] . Recently, a new memory T cell subset, stem cell memory T (T SCM ), which has stem cell-like capacity, has been discovered [4] [5] [6] . However, little is known about the role of these cells in AML. In this study, we assessed the distribution of CD4+ and CD8+ T SCM , central memory T (T CM ), T effector memory (T EM ), and T terminal effector (T EF ) cells in peripheral blood (PB) and bone marrow (BM) from patients with AML and those with AML in complete remission (AML-CR) by multicolor flow cytometry. The gating strategy used in this study followed a published protocol [7] . The CD4+ and CD8+ T cells were divided into four subgroups according to the CCR7 and CD45RO expression pattern: naïve and T SCM cells (CCR7+CD45RO−), T CM cells (CCR7 +CD45RO+), T EM cells (CCR7−CD45RO+), and T EF cells (CCR7−CD45RO−). The T SCM population was defined by double positive CD95 and CD28 expression.
The percentages of the T SCM , T CM , T EM , and T EF cells in the CD4+ and CD8+ populations were analyzed in 20 cases with AML (17 cases in newly diagnosed and 3 cases with AML relapse) (Fig. 1a, d ) [8, 9] . The CD8+ T SCM and CD8+ T CM cells significantly decreased in the PB of these patients (Fig. 1e, g ), whereas there was no significant change in the CD4+ population (Fig. 1b,  g ). Thus, the changes in the memory T cell subsets appeared to mainly involve CD8+ T cells. The shift from T SCM and T CM cells to a higher ratio of differentiated T EM and T EF cells is thought to be due to the constant exposure of T cells to AML cells and the leukemia environment, leading to T cell exhaustion and/or dysfunction [3] .
To study the influence of the tumor microenvironment on the memory T cell distribution and function in leukemia patients, we collected seven pairs of PB and BM samples from AML patients at the time of diagnosis and compared the distributions of memory T cell subsets. The differences in each subset appeared to vary widely (Fig. 1c, f ) . A low percentage of CD4+ T CM cells and a corresponding high percentage of CD4+ T EM and T EF cells were observed in the BM compared with PB (Fig. 1c) . In the CD8+ population, the changes appeared to be specific to each individual, and lower CD8+ T SCM and CD8+ T CM percentages were observed in the BM in half of the patients, whereas there were high percentages of CD8+ T SCM and CD8+ T CM cells in the BM compared with PB in the remaining samples. It has been reported that T cells in normal BM mainly possess a memory phenotype, particularly for CD8+ T CM cells [10] , suggesting that alterations in the leukemic BM niche in different AML individuals and AML subtypes may have different impact on T CM homing.
Next, we compared the distribution of memory T cells in AML patients younger (AMLy) and older (AMLo) than 60 years [11] . Unlike healthy individuals (HIs), the memory T cell subset distribution in the AMLy cohort Fig. 1 Gating strategy for identifying the CD4+ and CD8+ T cells and the percentage of memory T cell subsets in the patients with AML and healthy individuals. a, d CD4+ (a) and CD8+ T (d) cells were differentiated into four subsets based on the expression of CCR7 and CD45RO in one HI-PB, one AML-PB, and one AML-BM patient: central memory T cells (CCR7+CD45RO+), effector memory T cells (CCR7−CD45RO+), and effector T cells (CCR7−CD45RO−). In the CCR7+CD45RO− subset, the expression of CD28 and CD95 was used to identify naïve T cells (CD28+CD95−) and T SCM cells (CD28+CD95+). b, e Frequency of the T SCM , T CM , T EM , and T EF subsets in the CD4+ (b) and CD8+ (e) T cell populations from 27 HIs and 20 AML patients. c, f The subsets within the CD4+ (c) and CD8+ (f) T cell populations from PB and matched BM from seven AML patients, including different AML subtypes (M1, M2, M2b, M3, and M5), were compared. g Summary of the altered distributions within the CD4 and CD8 naive and memory T cell subsets in the AMLy, AMLo, and AML-CR groups compared with HIs. HIy (n = 13), AMLy (n = 10), AML-CR (n = 9), HIo (n = 14), AMLo (n = 10). HIs, healthy individuals; AML, acute myeloid leukemia; AML-CR, AML patients who achieved complete remission; PB, peripheral blood; BM, bone marrow; y, younger than 60 years; and o, older than 60 years. The differences in the different T cell populations in each of the T cell subsets were tested by two independent-sample Wilcoxon tests. Medians were calculated to represent all of the data. P values < 0.05 were considered statistically significant was strikingly different than that in younger HIs (HIy) and tended to have a similar distribution pattern as that detected in the HIo and AMLo groups with a more obvious difference in the CD8+ population (Figs. 1g and  2a, b) . These findings indicate that the leukemia microenvironment might drive T cell differentiation in AMLy. Whether such a skewed T cell distribution in AMLy truly represents T cell senescence remains an open question [8] ; however, T cells in AMLo patients may not be able to further differentiate due to inherent T cell senescence, which may be an immune factor underlying the inferior prognosis of AMLo patients. Together, these data may suggest that T cell exhaustion and senescence are involved in T cell immune impairment, leading to an inefficient anti-tumor response.
We next compared differences in the distribution of memory T cell subsets between the AMLy, AML-CR, and HIy groups. A persistent, skewed memory T cell distribution was demonstrated for AML patients who achieved CR after chemotherapy (Fig. 2c, d ). CD4+ and CD8+ T SCM cells were predominantly increased at different time points after CR, while the change in other memory T cell subsets was relatively different (Fig. 2e,  f ) . Overall, with the exception of incomplete recovery of the T SCM cells, the reduction in T CM cells and corresponding excessive accumulation of T EM and T EF cells were more evident in AML patients with CR (Fig. 1g) , which may be related to the immune suppression of chemotherapy. 
